Phase I Safety and Immunogenicity Evaluation of MVA-CMDR, a Multigenic, Recombinant Modified Vaccinia Ankara-HIV-1 Vaccine Candidate

BACKGROUND: We conducted a Phase I randomized, dose-escalation, route-comparison trial of MVA-CMDR, a candidate HIV-1 vaccine based on a recombinant modified vaccinia Ankara viral vector expressing HIV-1 genes env/gag/pol. The HIV sequences were derived from circulating recombinant form CRF01_AE, wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Currier, Jeffrey R., Ngauy, Viseth, de Souza, Mark S., Ratto-Kim, Silvia, Cox, Josephine H., Polonis, Victoria R., Earl, Patricia, Moss, Bernard, Peel, Sheila, Slike, Bonnie, Sriplienchan, Somchai, Thongcharoen, Prasert, Paris, Robert M., Robb, Merlin L., Kim, Jerome, Michael, Nelson L., Marovich, Mary A.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2981570/
https://www.ncbi.nlm.nih.gov/pubmed/21085591
http://dx.doi.org/10.1371/journal.pone.0013983

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2981570/
https://www.ncbi.nlm.nih.gov/pubmed/21085591
http://dx.doi.org/10.1371/journal.pone.0013983

Ejemplares similares